647 related articles for article (PubMed ID: 16413803)
1. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening, molecular interaction field, molecular dynamics, docking, density functional, and ADMET properties of novel AChE inhibitors in Alzheimer's disease.
da Silva CH; Carvalho I; Taft CA
J Biomol Struct Dyn; 2007 Jun; 24(6):515-24. PubMed ID: 17508773
[TBL] [Abstract][Full Text] [Related]
3. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Ramírez L; Viayna E; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Bidon-Chanal A; Huertas O; Dafni T; Luque FJ
Chem Biol Interact; 2010 Sep; 187(1-3):411-5. PubMed ID: 20167211
[TBL] [Abstract][Full Text] [Related]
4. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.
Alonso D; Dorronsoro I; Rubio L; Muñoz P; García-Palomero E; Del Monte M; Bidon-Chanal A; Orozco M; Luque FJ; Castro A; Medina M; Martínez A
Bioorg Med Chem; 2005 Dec; 13(24):6588-97. PubMed ID: 16230018
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Shao D; Zou C; Luo C; Tang X; Li Y
Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
8. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
10. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
11. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
[TBL] [Abstract][Full Text] [Related]
12. Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylcholinesterase.
Girisha HR; Narendra Sharath Chandra JN; Boppana S; Malviya M; Sadashiva CT; Rangappa KS
Eur J Med Chem; 2009 Oct; 44(10):4057-62. PubMed ID: 19493592
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
[TBL] [Abstract][Full Text] [Related]
15. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
16. 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies.
Korabecny J; Dolezal R; Cabelova P; Horova A; Hruba E; Ricny J; Sedlacek L; Nepovimova E; Spilovska K; Andrs M; Musilek K; Opletalova V; Sepsova V; Ripova D; Kuca K
Eur J Med Chem; 2014 Jul; 82():426-38. PubMed ID: 24929293
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Thiratmatrakul S; Yenjai C; Waiwut P; Vajragupta O; Reubroycharoen P; Tohda M; Boonyarat C
Eur J Med Chem; 2014 Mar; 75():21-30. PubMed ID: 24508831
[TBL] [Abstract][Full Text] [Related]
19. Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.
Rizzo S; Bartolini M; Ceccarini L; Piazzi L; Gobbi S; Cavalli A; Recanatini M; Andrisano V; Rampa A
Bioorg Med Chem; 2010 Mar; 18(5):1749-60. PubMed ID: 20171894
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
